vs
合众银行（CUBI）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
合众银行的季度营收约是Orthofix Medical Inc.的1.1倍（$236.9M vs $219.9M），合众银行同比增速更快（21.8% vs 2.0%），合众银行自由现金流更多（$481.0M vs $16.8M），过去两年合众银行的营收复合增速更高（14.2% vs 8.0%）
合众银行是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的跨国银行机构，2025年位列美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性。旗下核心运营主体为美国合众银行全国协会，提供银行、投资、按揭等多元金融服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CUBI vs OFIX — 直观对比
营收规模更大
CUBI
是对方的1.1倍
$219.9M
营收增速更快
CUBI
高出19.8%
2.0%
自由现金流更多
CUBI
多$464.2M
$16.8M
两年增速更快
CUBI
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $236.9M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 41.1% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 21.8% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $2.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUBIOFIX
| Q4 25 | $236.9M | $219.9M | ||
| Q3 25 | $232.1M | $205.6M | ||
| Q2 25 | $206.3M | $203.1M | ||
| Q1 25 | $143.0M | $193.6M | ||
| Q4 24 | $167.8M | $215.7M | ||
| Q3 24 | $167.1M | $196.6M | ||
| Q2 24 | $198.7M | $198.6M | ||
| Q1 24 | $181.6M | $188.6M |
净利润CUBIOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $75.7M | $-22.8M | ||
| Q2 25 | $60.9M | $-14.1M | ||
| Q1 25 | $12.9M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $46.7M | $-27.4M | ||
| Q2 24 | $58.1M | $-33.4M | ||
| Q1 24 | $49.7M | $-36.0M |
毛利率CUBIOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CUBIOFIX
| Q4 25 | 41.1% | 0.2% | ||
| Q3 25 | 43.2% | -8.3% | ||
| Q2 25 | 38.2% | -7.9% | ||
| Q1 25 | 8.3% | -25.2% | ||
| Q4 24 | 21.4% | -5.3% | ||
| Q3 24 | 27.5% | -9.6% | ||
| Q2 24 | 38.8% | -12.5% | ||
| Q1 24 | 36.0% | -15.6% |
净利率CUBIOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 32.6% | -11.1% | ||
| Q2 25 | 29.5% | -6.9% | ||
| Q1 25 | 9.0% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 28.0% | -13.9% | ||
| Q2 24 | 29.2% | -16.8% | ||
| Q1 24 | 27.4% | -19.1% |
每股收益（稀释后）CUBIOFIX
| Q4 25 | $2.04 | $-0.05 | ||
| Q3 25 | $2.20 | $-0.57 | ||
| Q2 25 | $1.73 | $-0.36 | ||
| Q1 25 | $0.29 | $-1.35 | ||
| Q4 24 | $0.72 | $-0.76 | ||
| Q3 24 | $1.31 | $-0.71 | ||
| Q2 24 | $1.66 | $-0.88 | ||
| Q1 24 | $1.40 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.4B | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $450.0M |
| 总资产 | $24.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUBIOFIX
| Q4 25 | $4.4B | $82.0M | ||
| Q3 25 | $4.2B | $62.9M | ||
| Q2 25 | $3.5B | $65.6M | ||
| Q1 25 | $3.4B | $58.0M | ||
| Q4 24 | $3.8B | $83.2M | ||
| Q3 24 | $3.1B | $30.1M | ||
| Q2 24 | $3.0B | $26.4M | ||
| Q1 24 | $3.7B | $27.0M |
总债务CUBIOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CUBIOFIX
| Q4 25 | $2.1B | $450.0M | ||
| Q3 25 | $2.1B | $442.5M | ||
| Q2 25 | $1.9B | $458.3M | ||
| Q1 25 | $1.9B | $458.3M | ||
| Q4 24 | $1.8B | $503.1M | ||
| Q3 24 | $1.8B | $525.9M | ||
| Q2 24 | $1.7B | $546.0M | ||
| Q1 24 | $1.7B | $570.3M |
总资产CUBIOFIX
| Q4 25 | $24.9B | $850.6M | ||
| Q3 25 | $24.3B | $832.6M | ||
| Q2 25 | $22.6B | $837.2M | ||
| Q1 25 | $22.4B | $823.1M | ||
| Q4 24 | $22.3B | $893.3M | ||
| Q3 24 | $21.5B | $867.9M | ||
| Q2 24 | $20.9B | $882.0M | ||
| Q1 24 | $21.3B | $906.0M |
负债/权益比CUBIOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $494.8M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $481.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 203.0% | 7.6% |
| 资本支出强度资本支出/营收 | 5.8% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $843.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CUBIOFIX
| Q4 25 | $494.8M | $27.7M | ||
| Q3 25 | $116.9M | $12.4M | ||
| Q2 25 | $162.2M | $11.6M | ||
| Q1 25 | $94.1M | $-18.4M | ||
| Q4 24 | $145.1M | $23.7M | ||
| Q3 24 | $24.4M | $11.7M | ||
| Q2 24 | $6.1M | $9.0M | ||
| Q1 24 | $-18.8M | $-18.6M |
自由现金流CUBIOFIX
| Q4 25 | $481.0M | $16.8M | ||
| Q3 25 | $106.4M | $2.5M | ||
| Q2 25 | $162.1M | $4.5M | ||
| Q1 25 | $93.4M | $-25.1M | ||
| Q4 24 | $143.6M | $15.2M | ||
| Q3 24 | $24.1M | $6.3M | ||
| Q2 24 | $5.8M | $-360.0K | ||
| Q1 24 | $-19.2M | $-29.1M |
自由现金流率CUBIOFIX
| Q4 25 | 203.0% | 7.6% | ||
| Q3 25 | 45.9% | 1.2% | ||
| Q2 25 | 78.6% | 2.2% | ||
| Q1 25 | 65.4% | -13.0% | ||
| Q4 24 | 85.5% | 7.0% | ||
| Q3 24 | 14.4% | 3.2% | ||
| Q2 24 | 2.9% | -0.2% | ||
| Q1 24 | -10.6% | -15.4% |
资本支出强度CUBIOFIX
| Q4 25 | 5.8% | 4.9% | ||
| Q3 25 | 4.5% | 4.8% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.5% | 3.5% | ||
| Q4 24 | 0.9% | 4.0% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.2% | 4.7% | ||
| Q1 24 | 0.2% | 5.6% |
现金转化率CUBIOFIX
| Q4 25 | — | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 2.66× | — | ||
| Q1 25 | 7.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.10× | — | ||
| Q1 24 | -0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUBI
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
